Up 41% so far this year on hot sales of its drug Ozempic, Novo Nordisk (NYSE: NVO) isn't wasting any time in teeing up a few attempts at minting its next blockbuster. Ozempic 2.0 is already in the works, and there's no chance that it'll give up if there's a setback. 

But things don't move so quickly in the pharmaceutical industry, and buying shares right now, right after a big run-up, may not be the optimal strategy for investors to make the most of the company's next attempts.

So let's take a look at what it's doing, how long it might take for those efforts to pay off, and what investors can do to profit.

Continue reading

Source Fool.com